No Data
Here's Why Novo Nordisk A/S (NVO) Fell in Q3
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
European Medicines Agency's Committee For Medicinal Products For Human Use Adopted Positive Opinion For Update Of Novo Nordisk's Ozempic
Express News | Novo-Nordisk A/S: After the clinical trial results of the kidney therapy were released, the regulatory authorities in Europe gave a positive label evaluation to Ozempic.
Has Eli Lilly and Co's tirzepatide "defeated" Novo-Nordisk A/S's semaglutide? The competition for weight loss drugs is moving towards "precision breakthroughs."
Industry experts point out that the competition for weight loss drugs is no longer just about rapid weight loss, but requires a "targeted breakthrough" in safety and sustainability aspects, such as reducing weight regain, minimizing muscle loss, increasing medication convenience, and reducing side effects.